What is Lucid Diagnostics's market cap?

Lucid Diagnostics (LUCD) has a market capitalization of $188.9M and trades on NASDAQ.

What is Lucid Diagnostics's revenue and profitability?

Lucid Diagnostics generated $5.1M in trailing twelve-month revenue with a net loss of $45.0M, representing a net margin of -876.7%. Gross margin stands at -66.8%, with free cash flow of -$47.1M. These figures are based on the Q1 2026 filing.

Who are Lucid Diagnostics's competitors?

Lucid Diagnostics's key competitors include Guardant Health, PAVmed Inc. Common Stock, Cardio Diagnostics Holdings Inc. Common stock, and others. These companies compete in similar markets and product categories.

Who does Lucid Diagnostics partner with?

Lucid Diagnostics's notable partners include Case Western Reserve University, UpScript, LLC, Coastline International, and others.

What subsidiaries does Lucid Diagnostics have?

Lucid Diagnostics's subsidiaries include LucidDx Labs Inc., CapNostics, LLC.

Where is Lucid Diagnostics headquartered?

Lucid Diagnostics is headquartered in United States of America and employs approximately 70 people. It has been publicly traded since 2021.

Lucid Diagnostics

LUCD

Lucid Diagnostics is a commercial-stage medical technology company specializing in the early detection and prevention of esophageal cancer.

Market cap

$188.9M+48.0%

Revenue$5.1M+23.0%

Net income-$45.0M+27.2%

Free cash flow-$47.1M-40.1%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 14, 2026

Revenue$1.3MMiss by $124.3K EPS-$0.07Miss by $0.02

Read the full report

Next report

Aug 12, 2026 (in a month)

Revenue estimate$1.4M

EPS estimate-$0.04

Financials

Q1 2026

Income statement

See full

Revenue$1.3M+51.7%

Gross profit-$369.0K+49.0%

Operating income-$12.1M+3.0%

Net income-$13.9M+48.3%

Balance sheet

See full

Cash & equivalents$27.9M+10.6%

Total debt$1.6M-35.1%

Total equity$4.0M+174%

Total assets$34.1M+3.9%

Cash flow

See full

Operating cash flow-$12.1M+2.9%

CapEx$215.0K+131%

Free cash flow-$12.3M+1.9%

Valuation & ratios

Valuation

See full

Market cap$188.9M+48.0%

Enterprise value$162.63M+94.4%

P/S36.8×+11.0×

Profitability

See full

Operating margin-959.6%-133pp

Net margin-876.7%-254pp

Returns & leverage

See full

Debt / equity0.4×—

Current ratio1.1×+0.3×

Competitors

By market cap

Quest Diagnostics$23.0B+18.6%

Guardant Health$21.8B+254%

GeneDx Holdings$2.1B-15.8%

Personalis, Inc.$1.5B+160%

Lucid Diagnostics$188.9M+67.9%

PAVmed Inc.$39.7M+289%

Cardio Diagnostics Holdings Inc.$5.5M-16.9%

ONC

Onconetix, Inc.$3.6M+61.7%

By revenue growth

Guardant Health+39.6%

GeneDx Holdings+34.1%

Lucid Diagnostics+23.0%

Quest Diagnostics+11.0%

Personalis, Inc.-24.7%

By net margin

Quest Diagnostics9.08%+0.2pp

GeneDx Holdings-17.58%+1.9pp

Guardant Health-40.1%+13.7pp

Personalis, Inc.-148.11%-50.0pp

Lucid Diagnostics-876.72%+605pp

Profile

Lucid Diagnostics is a commercial-stage medical technology company specializing in the early detection and prevention of esophageal cancer. The company provides a non-invasive diagnostic platform designed to identify esophageal precancer in patients with chronic heartburn and gastroesophageal reflux disease (GERD). Its core value proposition is offering a patient-friendly, office-based alternative to traditional invasive endoscopy for widespread screening.

Competitive position

Lucid Diagnostics holds a first-mover advantage with the only commercially available non-invasive esophageal cell collection and DNA testing system endorsed by major clinical guidelines as an alternative to endoscopy.

GeographiesUnited States, European Union

Customer segmentsHealthcare Providers, Government Agencies, Corporate Employers

Business modelLaboratory Developed Tests (LDT), Medical Device Manufacturing, Direct Contracting

SuppliersContract Manufacturers, Academic Research Institutions, Logistics and Fulfillment Partners

CustomersMedicare and Medicaid Services, Commercial Insurance Payors, Physician Offices, Hospitals

CountryUnited States of America

Listed2021

Employees70.0

CEOLishan Aklog

SectorHealthcare

IndustryMedical - Devices

Websiteluciddx.com

FilingsSEC EDGAR

Ask your AI about Lucid Diagnostics.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Lucid Diagnostics's market cap?: Lucid Diagnostics (LUCD) has a market capitalization of $188.9M and trades on NASDAQ.
What is Lucid Diagnostics's revenue and profitability?: Lucid Diagnostics generated $5.1M in trailing twelve-month revenue with a net loss of $45.0M, representing a net margin of -876.7%. Gross margin stands at -66.8%, with free cash flow of -$47.1M. These figures are based on the Q1 2026 filing.
Who are Lucid Diagnostics's competitors?: Lucid Diagnostics's key competitors include Guardant Health, PAVmed Inc. Common Stock, Cardio Diagnostics Holdings Inc. Common stock, and others. These companies compete in similar markets and product categories.
Who does Lucid Diagnostics partner with?: Lucid Diagnostics's notable partners include Case Western Reserve University, UpScript, LLC, Coastline International, and others.
What subsidiaries does Lucid Diagnostics have?: Lucid Diagnostics's subsidiaries include LucidDx Labs Inc., CapNostics, LLC.
Where is Lucid Diagnostics headquartered?: Lucid Diagnostics is headquartered in United States of America and employs approximately 70 people. It has been publicly traded since 2021.